Since we found no incidence of oncogenic KRAS mutations in basal-like tumors, our results indicates that therapies based on EGFR inhibition may be of benefit in the treatment of this particularly agressive subtype of breast tumors. The gene discussed is EGFR; the disease is breast neoplasm.